<p>根据 MarketBeat.com 的报道，阿博维公司（NYSE:ABBV - 获取免费报告）的股票获得了 26 位分析师的共识推荐为 “适度买入”。七位分析师给予该股票持有评级，十六位给予买入评级，三位给予强烈买入评级。在过去一年中，对该股票发布评级的经纪商的平均 12 个月目标价为 210.71 美元。</p>
<ul>
<li>3 只生物制药股票逆势而上</li>
</ul>
<p>几家研究公司对阿博维进行了评论。Erste Group Bank 在 3 月 17 日的研究报告中将阿博维的股票评级上调至 “强烈买入”。摩根士丹利在 4 月 11 日的研究报告中重申了对阿博维股票的 “持有” 评级。瑞银集团在 2 月 3 日的研究报告中将阿博维的目标价从 181.00 美元上调至 190.00 美元，并给予该股票 “中性” 评级。富国银行在 3 月 5 日的报告中将阿博维的目标价从 210.00 美元上调至 240.00 美元，并给予公司 “增持” 评级。最后，花旗集团在 2 月 3 日的报告中将阿博维的目标价从 205.00 美元上调至 215.00 美元，并给予公司 “买入” 评级。</p>
<p><strong>获取我们最新的阿博维股票报告</strong></p>
<h2>阿博维股票表现</h2>
<ul>
<li>MarketBeat 周度回顾 – 03/24 - 03/28</li>
</ul>
<p>阿博维股票在周二开盘价为 170.01 美元。该公司的市值为 3007.4 亿美元，市盈率为 70.84，市盈增长比率为 1.62，贝塔值为 0.55。阿博维的 12 个月最低价为 153.58 美元，最高价为 218.66 美元。该公司的 50 日移动平均价格为 198.01 美元，200 日移动平均价格为 187.54 美元。公司的债务与股本比率为 17.94，流动比率为 0.66，速动比率为 0.55。</p>
<p>阿博维（NYSE:ABBV - 获取免费报告）最近一次发布季度财报是在 1 月 31 日。该公司报告的每股收益（EPS）为 2.16 美元，低于分析师的共识预期 2.98 美元，差额为 0.82 美元。阿博维的净利润率为 7.59%，股本回报率为 296.28%。去年同期，该公司每股收益为 2.79 美元。研究分析师预计阿博维今年的每股收益将达到 12.31 美元。</p>
<h2>阿博维宣布分红</h2>
<ul>
<li>阿博维股票通过进入减肥市场提升投资组合</li>
</ul>
<p>该公司最近宣布了一项季度分红，将于 5 月 15 日支付。4 月 15 日的股东将获得 1.64 美元的分红。这代表着每年 6.56 美元的分红和 3.86% 的收益率。该分红的除息日为 4 月 15 日。阿博维的分红支付比率（DPR）目前为 273.33%。</p>
<h2>阿博维的内部交易</h2>
<p>在相关消息中，执行副总裁 Perry C. Siatis 在 2 月 20 日的交易中出售了 5,778 股公司的股票。股票以平均价格 197.90 美元出售，总价值为 1,143,466.20 美元。出售完成后，该执行副总裁现在直接持有 22,381 股公司股票，价值为 4,429,199.90 美元。此次交易使其持股减少了 20.52%。该出售在向 SEC 的文件中披露，相关信息可在 SEC 网站上找到。此外，执行副总裁 Timothy J. Richmond 在 2 月 26 日的交易中出售了 29,917 股公司的股票。股票以平均价格 202.90 美元出售，总价值为 6,070,159.30 美元。交易完成后，该执行副总裁现在持有 44,284 股公司股票，价值为 8,985,223.60 美元。此次交易使其持股减少了 40.32%。该出售的披露信息可以在此找到。过去 90 天内，内部人士出售了 113,471 股公司股票，价值为 23,426,451 美元。内部人士持有该股票的比例为 0.25%。</p>
<h2>机构资金流入和流出</h2>
<p>对冲基金和其他机构投资者最近增加或减少了对该股票的持股。Fiduciary Advisors Inc.在第四季度购买了阿博维的新股份，价值约为 29,000 美元。EnRich Financial Partners LLC 在第四季度将其在阿博维的持股增加了 196.4%。EnRich Financial Partners LLC 现在拥有 166 股公司股票，价值 29,000 美元，此前在上个季度增持了 110 股。Promus Capital LLC 在第四季度购买了阿博维的新股份，价值 30,000 美元。Bradley &amp; Co. Private Wealth Management LLC 在第四季度购买了阿博维的新股份，价值约为 31,000 美元。最后，Prudent Man Investment Management Inc.在第四季度购买了阿博维的新股份，价值约为 32,000 美元。目前，70.23% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>关于阿博维</h2>
<p>（获取免费报告）</p>
<p>阿博维公司在全球范围内发现、开发、生产和销售药品。该公司提供 Humira，一种用于自身免疫性和肠道贝赫切特病及脓皮病的注射剂；Skyrizi 用于治疗中度至重度斑块型银屑病、银屑病性疾病和克罗恩病；Rinvoq 用于治疗类风湿性关节炎、银屑病性关节炎、强直性脊柱炎、特应性皮炎、轴性脊柱关节炎、溃疡性结肠炎和克罗恩病；Imbruvica 用于治疗成人血癌患者；Epkinly 用于治疗淋巴瘤；Elahere 用于治疗癌症；以及 Venclexta/Venclyxto 用于治疗血癌。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票超过阿博维</li>
<li>股票情绪分析：如何运作</li>
<li>AST SpaceMobile：购买这只小型开拓者股票的五个理由</li>
<li>万亿美元市值的意义超越数字</li>
<li>为什么看涨期权交易者现在瞄准这只分红 ETF</li>
<li>ESG 股票，投资者应了解的事项</li>
<li>Alphabet 被误解了吗？这就是为什么看涨者正在购买</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在艾伯维吗？</h2>
<p>在考虑艾伯维之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而艾伯维并不在名单上。</p>
<p>虽然艾伯维目前在分析师中获得了中性买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

艾伯维

<p>艾伯维（AbbVie Inc.，纽约证券交易所代码：ABBV）获得了 26 位分析师的 “适度买入” 共识推荐。12 个月的平均目标价为 210.71 美元，其中 16 位分析师建议买入，3 位建议强烈买入。最近的评级包括 Erste Group Bank 的 “强烈买入” 以及富国银行将目标价上调至 240 美元。艾伯维上个季度报告的每股收益为 2.16 美元，未达到预期，并宣布季度股息为 1.64 美元。内部交易显示高管进行了大量股票出售</p>

<p>Shares of AbbVie Inc. (NYSE:ABBV - Get Free Report) have been assigned a consensus recommendation of &#34;Moderate Buy&#34; from the twenty-six analysts that are covering the stock, MarketBeat.com reports. Seven analysts have rated the stock with a hold recommendation, sixteen have given a buy recommendation and three have issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $210.71.</p>
<div class="lb-trans"><p>根据 MarketBeat.com 的报道，阿博维公司（NYSE:ABBV - 获取免费报告）的股票获得了 26 位分析师的共识推荐为 “适度买入”。七位分析师给予该股票持有评级，十六位给予买入评级，三位给予强烈买入评级。在过去一年中，对该股票发布评级的经纪商的平均 12 个月目标价为 210.71 美元。</p>
</div><ul>
<li>3 Biopharmaceutical Stocks Bucking the Sell-Off</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只生物制药股票逆势而上</li>
</ul>
</div><p>Several research firms have commented on ABBV. Erste Group Bank raised shares of AbbVie to a &#34;strong-buy&#34; rating in a research note on Monday, March 17th. Morgan Stanley reaffirmed a &#34;hold&#34; rating on shares of AbbVie in a research note on Friday, April 11th. UBS Group raised their price objective on shares of AbbVie from $181.00 to $190.00 and gave the stock a &#34;neutral&#34; rating in a research note on Monday, February 3rd. Wells Fargo &amp; Company boosted their price target on shares of AbbVie from $210.00 to $240.00 and gave the company an &#34;overweight&#34; rating in a report on Wednesday, March 5th. Finally, Citigroup raised their target price on AbbVie from $205.00 to $215.00 and gave the company a &#34;buy&#34; rating in a report on Monday, February 3rd.</p>
<div class="lb-trans"><p>几家研究公司对阿博维进行了评论。Erste Group Bank 在 3 月 17 日的研究报告中将阿博维的股票评级上调至 “强烈买入”。摩根士丹利在 4 月 11 日的研究报告中重申了对阿博维股票的 “持有” 评级。瑞银集团在 2 月 3 日的研究报告中将阿博维的目标价从 181.00 美元上调至 190.00 美元，并给予该股票 “中性” 评级。富国银行在 3 月 5 日的报告中将阿博维的目标价从 210.00 美元上调至 240.00 美元，并给予公司 “增持” 评级。最后，花旗集团在 2 月 3 日的报告中将阿博维的目标价从 205.00 美元上调至 215.00 美元，并给予公司 “买入” 评级。</p>
</div><p><strong>Get Our Latest Stock Report on ABBV</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的阿博维股票报告</strong></p>
</div><h2>AbbVie Stock Performance</h2>
<div class="lb-trans"><h2>阿博维股票表现</h2>
</div><ul>
<li>MarketBeat Week in Review – 03/24 - 03/28</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周度回顾 – 03/24 - 03/28</li>
</ul>
</div><p>AbbVie stock opened at $170.01 on Tuesday. The company has a market cap of $300.74 billion, a PE ratio of 70.84, a P/E/G ratio of 1.62 and a beta of 0.55. AbbVie has a 12 month low of $153.58 and a 12 month high of $218.66. The company has a fifty day moving average price of $198.01 and a two-hundred day moving average price of $187.54. The company has a debt-to-equity ratio of 17.94, a current ratio of 0.66 and a quick ratio of 0.55.</p>
<div class="lb-trans"><p>阿博维股票在周二开盘价为 170.01 美元。该公司的市值为 3007.4 亿美元，市盈率为 70.84，市盈增长比率为 1.62，贝塔值为 0.55。阿博维的 12 个月最低价为 153.58 美元，最高价为 218.66 美元。该公司的 50 日移动平均价格为 198.01 美元，200 日移动平均价格为 187.54 美元。公司的债务与股本比率为 17.94，流动比率为 0.66，速动比率为 0.55。</p>
</div><p>AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings data on Friday, January 31st. The company reported $2.16 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.98 by ($0.82). AbbVie had a net margin of 7.59% and a return on equity of 296.28%. During the same period last year, the business posted $2.79 EPS. Research analysts expect that AbbVie will post 12.31 earnings per share for the current year.</p>
<div class="lb-trans"><p>阿博维（NYSE:ABBV - 获取免费报告）最近一次发布季度财报是在 1 月 31 日。该公司报告的每股收益（EPS）为 2.16 美元，低于分析师的共识预期 2.98 美元，差额为 0.82 美元。阿博维的净利润率为 7.59%，股本回报率为 296.28%。去年同期，该公司每股收益为 2.79 美元。研究分析师预计阿博维今年的每股收益将达到 12.31 美元。</p>
</div><h2>AbbVie Announces Dividend</h2>
<div class="lb-trans"><h2>阿博维宣布分红</h2>
</div><ul>
<li>AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market</li>
</ul>
<div class="lb-trans"><ul>
<li>阿博维股票通过进入减肥市场提升投资组合</li>
</ul>
</div><p>The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be given a $1.64 dividend. This represents a $6.56 annualized dividend and a yield of 3.86%. The ex-dividend date of this dividend is Tuesday, April 15th. AbbVie's dividend payout ratio (DPR) is currently 273.33%.</p>
<div class="lb-trans"><p>该公司最近宣布了一项季度分红，将于 5 月 15 日支付。4 月 15 日的股东将获得 1.64 美元的分红。这代表着每年 6.56 美元的分红和 3.86% 的收益率。该分红的除息日为 4 月 15 日。阿博维的分红支付比率（DPR）目前为 273.33%。</p>
</div><h2>Insider Transactions at AbbVie</h2>
<div class="lb-trans"><h2>阿博维的内部交易</h2>
</div><p>In related news, EVP Perry C. Siatis sold 5,778 shares of the business's stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $197.90, for a total value of $1,143,466.20. Following the completion of the sale, the executive vice president now directly owns 22,381 shares of the company's stock, valued at $4,429,199.90. The trade was a 20.52 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Timothy J. Richmond sold 29,917 shares of the business's stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $202.90, for a total value of $6,070,159.30. Following the completion of the transaction, the executive vice president now owns 44,284 shares in the company, valued at $8,985,223.60. The trade was a 40.32 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 113,471 shares of company stock worth $23,426,451 over the last ninety days. 0.25% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在相关消息中，执行副总裁 Perry C. Siatis 在 2 月 20 日的交易中出售了 5,778 股公司的股票。股票以平均价格 197.90 美元出售，总价值为 1,143,466.20 美元。出售完成后，该执行副总裁现在直接持有 22,381 股公司股票，价值为 4,429,199.90 美元。此次交易使其持股减少了 20.52%。该出售在向 SEC 的文件中披露，相关信息可在 SEC 网站上找到。此外，执行副总裁 Timothy J. Richmond 在 2 月 26 日的交易中出售了 29,917 股公司的股票。股票以平均价格 202.90 美元出售，总价值为 6,070,159.30 美元。交易完成后，该执行副总裁现在持有 44,284 股公司股票，价值为 8,985,223.60 美元。此次交易使其持股减少了 40.32%。该出售的披露信息可以在此找到。过去 90 天内，内部人士出售了 113,471 股公司股票，价值为 23,426,451 美元。内部人士持有该股票的比例为 0.25%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Fiduciary Advisors Inc. bought a new stake in shares of AbbVie in the fourth quarter valued at approximately $29,000. EnRich Financial Partners LLC lifted its holdings in shares of AbbVie by 196.4% during the 4th quarter. EnRich Financial Partners LLC now owns 166 shares of the company's stock worth $29,000 after acquiring an additional 110 shares during the last quarter. Promus Capital LLC purchased a new position in AbbVie in the fourth quarter worth $30,000. Bradley &amp; Co. Private Wealth Management LLC purchased a new stake in AbbVie during the fourth quarter valued at about $31,000. Finally, Prudent Man Investment Management Inc. bought a new stake in AbbVie during the fourth quarter worth about $32,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近增加或减少了对该股票的持股。Fiduciary Advisors Inc.在第四季度购买了阿博维的新股份，价值约为 29,000 美元。EnRich Financial Partners LLC 在第四季度将其在阿博维的持股增加了 196.4%。EnRich Financial Partners LLC 现在拥有 166 股公司股票，价值 29,000 美元，此前在上个季度增持了 110 股。Promus Capital LLC 在第四季度购买了阿博维的新股份，价值 30,000 美元。Bradley &amp; Co. Private Wealth Management LLC 在第四季度购买了阿博维的新股份，价值约为 31,000 美元。最后，Prudent Man Investment Management Inc.在第四季度购买了阿博维的新股份，价值约为 32,000 美元。目前，70.23% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>About AbbVie</h2>
<div class="lb-trans"><h2>关于阿博维</h2>
</div><p>(Get Free Report</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p>
<div class="lb-trans"><p>阿博维公司在全球范围内发现、开发、生产和销售药品。该公司提供 Humira，一种用于自身免疫性和肠道贝赫切特病及脓皮病的注射剂；Skyrizi 用于治疗中度至重度斑块型银屑病、银屑病性疾病和克罗恩病；Rinvoq 用于治疗类风湿性关节炎、银屑病性关节炎、强直性脊柱炎、特应性皮炎、轴性脊柱关节炎、溃疡性结肠炎和克罗恩病；Imbruvica 用于治疗成人血癌患者；Epkinly 用于治疗淋巴瘤；Elahere 用于治疗癌症；以及 Venclexta/Venclyxto 用于治疗血癌。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than AbbVie</li>
<li>Stock Sentiment Analysis: How it Works</li>
<li>AST SpaceMobile: 5 Reasons to Buy This Tiny Trailblazer Stock</li>
<li>The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number</li>
<li>Why Call Option Traders Are Targeting This Dividend ETF Now</li>
<li>ESG Stocks, What Investors Should Know</li>
<li>Is Alphabet Misunderstood? Here’s Why the Bulls Are Buying</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过阿博维</li>
<li>股票情绪分析：如何运作</li>
<li>AST SpaceMobile：购买这只小型开拓者股票的五个理由</li>
<li>万亿美元市值的意义超越数字</li>
<li>为什么看涨期权交易者现在瞄准这只分红 ETF</li>
<li>ESG 股票，投资者应了解的事项</li>
<li>Alphabet 被误解了吗？这就是为什么看涨者正在购买</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NYSE&amp;Symbol=ABBV"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in AbbVie Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在艾伯维吗？</h2>
</div><p>Before you consider AbbVie, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑艾伯维之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而艾伯维并不在名单上。</p>
</div><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然艾伯维目前在分析师中获得了中性买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

艾伯维公司（NYSE: ABBV）被券商平均推荐为 “适度买入”